RxDoctor Payments Data

Edwin Guzman, PA

Physician Assistant · Hanford, CANPI 1881290252

Payments from drug & device makers

$4,080in general payments, 2019–2025

Across 180 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$763
  • Johnson & Johnson$689
  • Arcutis Biotherapeutics, Inc.$665
  • AbbVie$521
  • Organon$323
  • Sanofi$265
  • plus $854 from 11 others

What the payments were for

  • Food & beverage$3,96797%
  • Education$1123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,080 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$228,408
Medicare patients
357
Services billed
3,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate26$48,917
ZoryveRoflumilast23$19,021
VtamaTapinarof13$18,906
Tacrolimus40$5,211
Pimecrolimus18$4,104
Calcipotriene15$3,332
Fluocinonide56$2,913
Betamethasone Dipropionate49$2,117
Metronidazole36$1,849
Clobetasol Propionate29$1,283
Clindamycin Phosphate39$1,089
Ketoconazole69$1,059
Gentamicin Sulfate20$929
Doxycycline Hyclate33$690
Ciclopirox16$600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$763$48,91726 claims
Arcutis Biotherapeutics, Inc.Zoryve$665$19,02123 claims
Dermavant Sciences, Inc.Vtama$146$18,90613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →